Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Pierce

Showing results (311-320 of 341) with videos related to

Pageof 35
Sort By:
Journal of Virology|January 18, 2019
Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect CellsRichard A Urbanowicz, Ruixue Wang, John E Schiel, et al.
Acta Crystallographica. Section F, Structural Biology Communications|February 2, 2024
Crystal structure and biophysical characterization of IspD from Burkholderia thailandensis and Mycobacterium paratuberculosisPhillip G Pierce, Brian E Hartnett, Tosha M Laughlin, et al.
Plos Pathogens|May 18, 2019
Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine designZhen-Yong Keck, Brian G Pierce, Patrick Lau, et al.
Journal of Virology|September 4, 2020
Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-NeutralizationBrian G Pierce, Zhen-Yong Keck, Ruixue Wang, et al.
Hepatology (Baltimore, Md.)|September 20, 2016
Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in miceZhen-Yong Keck, Yong Wang, Patrick Lau, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2021
Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimerJohnathan D Guest, Ruixue Wang, Khadija H Elkholy, et al.
Scientific Reports|February 3, 2021
Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine designAlla Amcheslavsky, Aaron L Wallace, Monir Ejemel, et al.
Acta Crystallographica. Section F, Structural Biology Communications|March 4, 2025
Analysis of Burkholderia pseudomallei IspF in complex with sulfapyridine, sulfamonomethoxine, ethoxzolamide and acetazolamideDakota Grote, Christopher G Stewart, Drashti G Daraji, et al.
Gastroenterology|October 16, 2021
An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine DevelopmentJordan H Salas, Richard A Urbanowicz, Johnathan D Guest, et al.
Frontiers in Immunology|September 29, 2022
Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variantsQi Li, Fiachra Humphries, Roxie C Girardin, et al.
Pageof 35

Showing results (311-320 of 341) with videos related to

Sort By:
Pageof 35
Journal of Virology|January 18, 2019
Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect CellsRichard A Urbanowicz, Ruixue Wang, John E Schiel, et al.
Acta Crystallographica. Section F, Structural Biology Communications|February 2, 2024
Crystal structure and biophysical characterization of IspD from Burkholderia thailandensis and Mycobacterium paratuberculosisPhillip G Pierce, Brian E Hartnett, Tosha M Laughlin, et al.
Plos Pathogens|May 18, 2019
Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine designZhen-Yong Keck, Brian G Pierce, Patrick Lau, et al.
Journal of Virology|September 4, 2020
Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-NeutralizationBrian G Pierce, Zhen-Yong Keck, Ruixue Wang, et al.
Hepatology (Baltimore, Md.)|September 20, 2016
Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in miceZhen-Yong Keck, Yong Wang, Patrick Lau, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2021
Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimerJohnathan D Guest, Ruixue Wang, Khadija H Elkholy, et al.
Scientific Reports|February 3, 2021
Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine designAlla Amcheslavsky, Aaron L Wallace, Monir Ejemel, et al.
Acta Crystallographica. Section F, Structural Biology Communications|March 4, 2025
Analysis of Burkholderia pseudomallei IspF in complex with sulfapyridine, sulfamonomethoxine, ethoxzolamide and acetazolamideDakota Grote, Christopher G Stewart, Drashti G Daraji, et al.
Gastroenterology|October 16, 2021
An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine DevelopmentJordan H Salas, Richard A Urbanowicz, Johnathan D Guest, et al.
Frontiers in Immunology|September 29, 2022
Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variantsQi Li, Fiachra Humphries, Roxie C Girardin, et al.
Pageof 35